Physicochemical characterization and dissolution enhancement of aceclofenac-hydroxypropyl β-cyclodextrin binary systems

PDA Journal of Pharmaceutical Science and Technology

Volumn 60, Issue 6, 2006, Pages 378-388

  Dahiya, Sunita ^a   Pathak, Kamla ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

Author keywords

Aceclofenac; BCS classification; Dissolution enhancement; Inclusion complexation; Phase solubility studies; Poorly water soluble drugs

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ACECLOFENAC; BETA CYCLODEXTRIN DERIVATIVE; DICLOFENAC; DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHEMISTRY; COST CONTROL; DIFFERENTIAL SCANNING CALORIMETRY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SOLUTION AND SOLUBILITY; THERMOGRAVIMETRY; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHYSICAL; COST CONTROL; DICLOFENAC; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; SOLUTIONS; SPECTROPHOTOMETRY, ULTRAVIOLET; THERMOGRAVIMETRY;

EID: 33847299631     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Duchene, D.; Wouessidjewe, D. Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev. Ind. Pharm. 1990, 16, 2487-2499.
2. Bekers, O.; Uijtendal, E. V.; Beijnen, J. H.; Bult, A.; Underberg, W. J. Cyclodextrins in pharmaceutical field. Drug Dev. Ind. Pharm. 1991, 17, 1503-1549.
3. Mishra, P. R.; Mishra, M.; Namdeo, A.; Jain, N. K. Pharmaceutical potential of cyclodextrins, Ind. J. Pharm. Sci. 1999, 61(4), 193-198.
4. Sweetman, S. C.; Martindale: The Complete Drug Reference, 33rd edition; The Pharmaceutical Press: London, 2002; p 11.
5. Higuchi, T.; Connors, K. A. Phase Solubility Techniques. In: Advances in Analytical Chemistry Instrumentation, Reilly, C. N., Ed.; Interscience: New York, 1965, Vol. 4; p 117.
6. Amidon, G. L.; Lobenberg, R.; Vieira, M. Solubility as a Limiting Factor to Drug Absorption. In Oral Drug Absorption: Prediction and Assessment, Dressman, J. B., Lennernas, H., Eds.; Marcel Dekker, Inc.: New York, 2000; p 137.
7. United States Pharmacopoeia 23, NF 18, Asian edition, 1995; p 2053.
8. Guidance for Industry: Dissolution Testing of Immediate Release Solid Dosage Forms, United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 1997; p 1-17.
9. Manolikar, M. K.; Sawant, M. R. Study of solubility of isoproturon by its complexation with β-cyclodextrin, Chemosphere 2003, 51, 811-816.
10. Nalluri, B. N.; Chowdary, K. P. R.; Murthy, K. V. R.; Hayman, A. R.; Becket, G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 2003, 4 (1), 1-12.
11. Ammar, H. O.; Salama, H. A.; Ghorab, M.; Mahmoud, A. A. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems. Int. J. Pharm. 2006, 309 (1-2), 129-138.
12. Winters, C. S.; York, P.; Timmins, P. Solid state examination of gliclazide-β-cyclodextrin complexes. Eur. J. Pharm. Sci. 1997, 5, 209-214.
13. 1H NMR and ROESY experiments. Eur. J. Pharm. Sci. 2003, 18, 285-296.
14. Masson, M.; Loftsson, T.; Jondottir, S.; Fridriksdottir, H.; Peterson, D. S. Stabilization of ionic drugs through complexation with non-ionic and ionic cyclodextrins. Int. J. Pharm. 1998, 164, 45-55.
15. Naidu, N. B.; Chowdary, K. P. R.; Murthy, K. V. R.; Satyanarayana, V.; Hayman, A. R.; Becket, G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharm. Biomed. Anal. 2004, 35, 75-86.
16. Soliman, O. A.; Kimura, K.; Hirayama, F.; Uekama, K.; El-Sabbagh, H. M.; El-Gawad, A. E.; Hashim, F. M. Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int. J. Pharm. 1997, 149 (1), 73-83.
17. Nagarsenkar, M. S.; Tantry, J. S.; Shenai, H. Influence of Hydroxypropyl-β-cyclodextrin on the dissolution of ketoprofen and irritation to gastric mucosa after oral administration in rats. Pharm. Sci. 1997, 3 (9), 443-445.
18. Badawy, S. I. F.; Ghorab, M. M.; Adeyene, C. Study of the complexation between danazol and hydrophilic cyclodextrin derivatives. Pharm. Res. 1995, 12 (9), S204.
19. Khan, K. A. The concept of dissolution efficiency. J. Pharm. Pharmacol. 1975, 27, 48-49.
20. Donbrow, M.; Tomitou, E. Estimation of dissolution rate of salicylamide in complexing media using a theoretical diffusion model. J. Pharm. Sci. 1978, 67, 95-98.
21. Uekama, K.; Narisawa, S.; Hirayama, F.; Otagiri, M. Improvement of dissolution and absorption characteristics of benzodiazepine-cyclodextrin complexation. Int. J. Pharm. 1983, 6, 327-338.
22. Gandhi, R. B.; Karara, A. H. Characterization, dissolution and diffusion properties of tolbutamide-β-cyclodextrin complex systems. Drug Dev. Ind. Pharm. 1988, 14, 657-682.
23. Loftsson, T. Cyclodextrins and the biopharmaceutics classification system of drugs. J. Inclus. Phenom. Macrocycl. Chem. 2002, 44, 63-67.